Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Community-acquired pneumonia.

Thomas M File1

  • 1Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, and Infectious Disease Service, Summa Health System, Akron, Ohio, USA. filet@summa-health.org

Lancet (London, England)
|December 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidance for the Knowledge and Skills required for Antimicrobial Stewardship Leaders: an update from the Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Use of Procalcitonin as a Tool to Enhance Antimicrobial Stewardship.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial.

EClinicalMedicine·2025
Same author

Pulmonary Infections in Adults: Community-Acquired Pneumonia.

FP essentials·2025
Same author

Pulmonary Infections in Adults: Nosocomial Pneumonia.

FP essentials·2025
Same author

Pulmonary Infections in Adults: Pulmonary Infections in Immunocompromised Patients.

FP essentials·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Community-acquired pneumonia (CAP) management for adults is evolving due to antimicrobial resistance and new pathogen data. Timely antibiotics, appropriate drug selection, and vaccinations are key for better patient outcomes.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Clinical Microbiology

Background:

  • Community-acquired pneumonia (CAP) remains a significant health concern in immunocompetent adults.
  • Emerging antimicrobial resistance in Streptococcus pneumoniae impacts empirical treatment strategies.
  • Identification of atypical pathogens necessitates further research into their clinical significance.

Purpose of the Study:

  • To review current information on the etiology, clinical course, diagnostics, treatment, and prevention of CAP.
  • To highlight management issues relevant to immunocompetent adults.
  • To discuss recent guideline recommendations for CAP management.

Main Methods:

  • Review of current literature and recent guideline publications on community-acquired pneumonia.

Related Experiment Videos

  • Analysis of emerging trends in causative pathogens, diagnostic approaches, and therapeutic strategies.
  • Discussion of factors influencing clinical outcomes and prevention methods.

    • Main Results:

    • Streptococcus pneumoniae is the primary pathogen, but resistance is increasing.
    • Atypical pathogens are frequently identified, though their clinical impact is often unclear due to diagnostic limitations.
    • Empirical antimicrobial therapy remains standard, guided by pathogen spectrum and pharmacokinetic/pharmacodynamic principles.

    Conclusions:

    • Timely antimicrobial administration, appropriate antibiotic selection, and adherence to clinical pathways improve CAP outcomes.
    • Vaccination against pneumococcal disease and influenza is crucial for prevention.
    • Updated guidelines offer valuable recommendations for managing CAP in immunocompetent adults.